Nanomedicine in the ROS-mediated pathophysiology: Applications and clinical advances.
Nanomedicine in the ROS-mediated pathophysiology: Applications and clinical advances.
复制标题
DOI：
10.1016/j.nano.2015.07.003
复制
发表时间：
2015-11
期刊：
影响因子：
--
通讯作者：
Ahmed S
中科院分区：
文献类型：
--
作者：
Nash KM;Ahmed S
活性氧（ROS）在调节正常细胞生理功能中是重要的，但当其过量产生时，会导致各种疾病的发病机制增强。在这些缺血再灌注损伤中，阿尔茨海默病和类风湿性关节炎尤为重要。由于ROS可以被各种抗氧化剂抵消，因此已经开发了天然和合成抗氧化剂。然而，由于活性氧在生命系统中普遍存在，这些药物的体内效率差，缺乏靶点特异性，目前治疗氧化应激损伤的临床模式是有限的。在纳米医学的发展领域的进展已经产生了纳米颗粒，可以延长抗氧化剂的活性和这些药剂的靶向特异性。因此，催化抗氧化剂如重组超氧化物歧化酶（SOD）与铂和氧化铈纳米颗粒组合在较小剂量下表现出更高的功效，具有潜在的较低毒性。本文综述了抗氧化剂纳米颗粒及其在氧化应激介导的疾病中的应用。
Reactive oxygen species (ROS) are important in regulating normal cell physiological functions, but when produced in excess lead to the augmented pathogenesis of various diseases. Among these ischemia reperfusion injury, Alzheimer’s disease and rheumatoid arthritis, are particularly important. Since ROS can be counteracted by a variety of antioxidants, natural and synthetic antioxidants have been developed. However, due to the ubiquitous production of ROS in living systems, poor in vivo efficiency of these agents and lack of target specificity, the current clinical modalities to treat oxidative stress damage are limited. Advances in the developing field of nanomedicine have yielded nanoparticles that can prolong antioxidant activity, and target specificity of these agents. Thus, catalytic antioxidants such as recombinant superoxide dismutase (SOD), in combination with platinum and cerium oxide nanoparticles manifest higher efficacy at smaller doses with potentially lower toxicity. This article reviews recent advances in antioxidant nanoparticles and their applications to manage oxidative stress-mediated diseases.